Myovant Sciences Stock Forecast, Price & News

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

Is Myovant Sciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Myovant Sciences stock.
View analyst ratings for Myovant Sciences or view top-rated stocks.

How has Myovant Sciences' stock been impacted by COVID-19?

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MYOV stock has increased by 87.7% and is now trading at $16.33.
View which stocks have been most impacted by COVID-19.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Myovant Sciences.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) announced its earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.11. During the same period in the previous year, the business earned ($0.75) EPS.
View Myovant Sciences' earnings history.

What price target have analysts set for MYOV?

6 brokers have issued 1-year price targets for Myovant Sciences' shares. Their forecasts range from $18.00 to $32.00. On average, they anticipate Myovant Sciences' share price to reach $25.40 in the next year. This suggests a possible upside of 55.5% from the stock's current price.
View analysts' price targets for Myovant Sciences or view top-rated stocks among Wall Street analysts.

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the following people:

• David C. Marek, Chief Executive Officer & Director
• Jeffrey D. Nornhold, Senior VP-Pharmaceutical Operations & Development
• Uneek Mehra, Chief Financial & Business Officer
• Juan Camilo Arjona Ferreira, Chief Medical Officer
• Matthew Lang, Secretary, Chief Administrative & Legal Officer (LinkedIn Profile)

Who are some of Myovant Sciences' key competitors?

Some companies that are related to Myovant Sciences include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Allakos (ALLK), I-Mab (IMAB), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Karuna Therapeutics (KRTX), ACADIA Pharmaceuticals (ACAD) and Zentalis Pharmaceuticals (ZNTL).
View all of MYOV's competitors.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (7.17%), Bellevue Group AG (6.18%), Janus Henderson Group PLC (6.09%), BlackRock Inc. (1.22%), Lord Abbett & CO. LLC (0.57%) and Hennion & Walsh Asset Management Inc. (0.46%). Company insiders that own Myovant Sciences stock include Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, Matthew Lang and Sciences Ltd Roivant.
View institutional ownership trends for Myovant Sciences.

Which institutional investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Jane Street Group LLC, Citigroup Inc., Goldman Sachs Group Inc., Blueshift Asset Management LLC, Millennium Management LLC, Connor Clark & Lunn Investment Management Ltd., and Integral Health Asset Management LLC. Company insiders that have sold Myovant Sciences company stock in the last year include Ferreira Juan Camilo Arjona, Frank Karbe, and Matthew Lang.
View insider buying and selling activity for Myovant Sciences or view top insider-selling stocks.

Which institutional investors are buying Myovant Sciences stock?

MYOV stock was bought by a variety of institutional investors in the last quarter, including Bellevue Group AG, Janus Henderson Group PLC, Wellington Management Group LLP, Royal Bank of Canada, Jump Financial LLC, BlackRock Inc., UBS Group AG, and Altshuler Shaham Ltd. Company insiders that have bought Myovant Sciences stock in the last two years include Chemical Co Ltd Sumitomo, and Sciences Ltd Roivant.
View insider buying and selling activity for Myovant Sciences or or view top insider-buying stocks.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $16.33.

How much money does Myovant Sciences make?

Myovant Sciences has a market capitalization of $1.52 billion and generates $59.32 million in revenue each year. The company earns $-255.13 million in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Myovant Sciences have?

Myovant Sciences employs 407 workers across the globe.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is www.myovant.com.

Where are Myovant Sciences' headquarters?

Myovant Sciences is headquartered at 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 442074003351 or via email at [email protected].